Valo Therapeutics Ltd, a UK spinout from the University of Helsinki, Finland with a novel approach for vaccinating against cancers, has named Michael Stein as chief executive. Dr Stein has led many university start-ups, breaking the UK record for a seed round with a £16.9 million funding in 2016 for OxStem Ltd. Valo Therapeutics is developing a proprietary, and genetically modified, adenovirus, coupled with tumour-specific peptides that can both directly target cancer cells and elicit a strong and lasting specific anti-tumour immune response.
Valo Therapeutics announced the appointment on 17 June 2019
Copyright 2019 Evernow Publishing Ltd